Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gaviscon Original Liquid is an over-the-counter antacid and reflux suppressant used for the symptomatic relief of heartburn and acid indigestion. It contains a combination of three active ingredients: sodium alginate, sodium bicarbonate, and calcium carbonate. The medication employs a dual-action mechanism of action. Upon contact with gastric acid, the sodium alginate forms a thick, physical barrier known as an alginate raft that floats on top of the stomach contents, physically preventing the reflux of acid into the esophagus. Simultaneously, the calcium carbonate and sodium bicarbonate act as chemical antacids to neutralize excess stomach acid. This localized action provides relief for up to four hours without entering the bloodstream. The product is sugar-free, gluten-free, and is currently marketed by Haleon (formerly part of GlaxoSmithKline).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gaviscon Original Liquid.